NCT07079735RecruitingPhase 2/3
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)
Source: ClinicalTrials.gov · Last updated 2 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 9 Jul 2025
- Start date
- 12 Sept 2025
- Primary completion date
- 17 Jan 2028
- Lead sponsor
- Columbia University
- NCT number
- NCT07079735
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 150
- From 12 Sept 2025 to the primary completion date, 17 Jan 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of or suspected CMV disease within 6 months prior is excluded.
Who the study is looking for
- Patients who are \>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NYP-Weill Cornell Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| Columbia University/NYP Milstein Hospital Coordinator of this site? Confirm its status | New York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.